Ondine Announces Acquisition of Exclusive License for Gold-Nanoparticle Photosensitizer



    VANCOUVER, July 29 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM:
OBP), a medical technology company developing photodisinfection-based
products, today announced that it has acquired an exclusive license for the
human therapeutic use of a gold-nanoparticle photosensitizer from UCL Business
PLC, the technology transfer company of University College London, London, UK.
    "In vitro studies have shown that this advanced compound is one of the
most potent photodisinfection agents ever developed," stated
Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The compound has
proven highly efficacious in killing Methicillin/multi-drug Resistant
Staphylococcus aureus, (MRSA), a prominent hospital-acquired pathogen. We
intend to further develop this new agent for integration into our
Photodisinfection System for various medical applications."

    About Ondine Biopharma Corporation

    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on developing and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is based in Vancouver, British Columbia,
Canada, with a research laboratory in Bothell, Washington, and an
international office in St Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com

    Forward-Looking Statements:

    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

    The TSX Exchange has not reviewed and does not accept responsibility for
    the adequacy or accuracy of this release.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Adam Peeler, Investor Relations, The Equicom Group
Inc., (416) 815-0700 ext. 225, apeeler@equicomgroup.com; Canaccord Adams Ltd,
Nominated Adviser & Broker, Neil Johnson, Ryan Gaffney, +4420 7050 6500

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890